RVO is one of the most common causes of blindness. Authorized drugs for treatment of RVO are injected directly into the eye and have no direct effect on the blockage of blood vessels that causes the disease. By contrast, the Company's drug candidate ANXV, which is administered intravenously, has the potential to directly counteract the blockage of blood vessels as well as the retinal swelling and the inflammatory processes caused by RVO.
The Phase 2 study is placebo-controlled and is expected to involve approximately 20 patients at five trial centers in
"Our hope is that ANXV will prove to be a safe and effective treatment for patients with RVO. ANXV has the potential to offer these patients a significantly better vision than they get with current medications," says Anna Frostegård, the Company's Chief Scientific and Medical Officer.
"The dosing of the first patient in our US-based Phase 2 study is a significant milestone for our company. We are now focusing on carrying out the study, and we hope for exciting results," says the Company's CEO,
About
The Company is based in
For further information, please contact:
The information was submitted for publication at 11:30 on
https://news.cision.com/annexin-pharmaceuticals-ab/r/first-patient-dosed-in-annexin-s-phase-2-study-in-retinal-vein-occlusion-,c3663319
https://mb.cision.com/Main/15539/3663319/1655408.pdf
(c) 2022 Cision. All rights reserved., source